TY - JOUR T1 - Artificial intelligence for the echocardiographic assessment of valvular heart disease JF - Heart JO - Heart SP - 1592 LP - 1599 DO - 10.1136/heartjnl-2021-319725 VL - 108 IS - 20 AU - Rashmi Nedadur AU - Bo Wang AU - Wendy Tsang Y1 - 2022/10/01 UR - http://heart.bmj.com/content/108/20/1592.abstract N2 - Developments in artificial intelligence (AI) have led to an explosion of studies exploring its application to cardiovascular medicine. Due to the need for training and expertise, one area where AI could be impactful would be in the diagnosis and management of valvular heart disease. This is because AI can be applied to the multitude of data generated from clinical assessments, imaging and biochemical testing during the care of the patient. In the area of valvular heart disease, the focus of AI has been on the echocardiographic assessment and phenotyping of patient populations to identify high-risk groups. AI can assist image acquisition, view identification for review, and segmentation of valve and cardiac structures for automated analysis. Using image recognition algorithms, aortic and mitral valve disease states have been directly detected from the images themselves. Measurements obtained during echocardiographic valvular assessment have been integrated with other clinical data to identify novel aortic valve disease subgroups and describe new predictors of aortic valve disease progression. In the future, AI could integrate echocardiographic parameters with other clinical data for precision medical management of patients with valvular heart disease. ER -